Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
24 nov 2014 - 07:45
Statutaire naam
Galapagos NV
Titel
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
Bericht
Mechelen, Belgium; 24 November 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 2 study with GLPG0634 has been completed. The Darwin Phase 2B program is now fully recruited and will begin a series of topline readouts starting around end of the first quarter 2015.
Selective JAK1 inhibitor GLPG0634 has shown a best-in-class profile in two 4-week Phase 2A studies in RA patients. GLPG0634 is currently in a global Phase 2B program (DARWIN) of 875 RA patients and in a Phase 2 study in 180 patients with Crohn's disease.
Datum laatste update: 01 september 2024